India will get COVID-19 vaccine by April-May, real question is how long it will protect us: Serum Institute's Adar Poonawalla
SII has partnered with five global pharma companies including AstraZeneca to produce one billion doses of its vaccine candidate half of which it has pledged to India.
Oxford-AstraZeneca Covid-19 vaccine: Phase II trials finds it safe in older healthy adults
The Oxford-AstraZeneca combine's Covid-19 vaccine candidate is seen to be safe in older, healthy adults, according early stage results published in Th ASTRAZENECA PHARMA INDIA LTD. - 506820 - Clarification
With reference to Movement in Volume, AstraZeneca Pharma India Ltd has submitted to BSE a copy of Clarification is enclosed.
COVID-19 update | India to get 100 million AstraZeneca's vaccine shots by December 2020: Reports
Serum Institute of India plans to have 100 million doses ready by December 2020 for an inoculation drive that could begin across India that same month, say reports ASTRAZENECA PHARMA INDIA LTD. - 506820 - Clarification sought from AstraZeneca Pharma India Ltd
The Exchange has sought clarification from AstraZeneca Pharma India Ltd on November 13, 2020, with reference to Movement in Volume.The reply is awaited. Serum to have 200 mn doses of AstraZeneca coronavirus vaccine ready by Jan
Pune company recruits over 1,600 participants in India for phase 3 trials of Covishield. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing a copy of newspaper advertisement published in Business Standard and Prajavani newspapers. COVID-19 vaccine update: India looks to Covaxin as AstraZeneca's deliveries run late
India may concentrate its efforts on Bharat Biotech's Covaxin as AstraZeneca's COVID-19 vaccine deliveries may be delayed. The months of November and December could be critical in terms of vaccine availability as a number of companies are likely to publish late-stage trial data AstraZeneca's Covid-19 vaccine to begin clinical trials in China this year
AstraZeneca plans to start early and mid-stage clinical trials of its Covid-19 vaccine candidate in China this year, a senior executive said, as it prepares a global rollout of the vaccine ASTRAZENECA PHARMA INDIA LTD. - 506820 - Outcome Of The Board Meeting Held On Thursday, November 5, 2020
At the Board meeting of the Company held on Thursday, November 5, 2020 the Board of Directors considered and approved the Unaudited Financial Results of the Company for the quarter ended September 30, 2020. The said Unaudited Financial Results together with the Limited Review report of the Statutory Auditors dated November 5, 2020 are enclosed herewith.